Insight

Gunsagar Gulati: Two extraordinary papers released on BioRxiv

Photo from Gunsagar Gulati/X

Jul 31, 2024, 11:17

Gunsagar Gulati: Two extraordinary papers released on BioRxiv

Gunsagar Gulati, Clinical Fellow at Dana-Farber Cancer Institute, shared a post on X about two recent articles, commenting:

“Two extraordinary papers released today on BioRxiv:

Mechanism behind cardiac benefit from SGLT2i, The Arany lab.
Novel strategy for drugging P53-mutant cancers, William Gibson.

It’s an exciting time to be in physician-science!”

SGLT2 inhibitors activate pantothenate kinase in the human heart

Authors: Nicholas Forelli, Deborah Eaton, Jiten Patel, Caitlyn Bowman, Ryo Kawakami, Ivan Kuznetsov, Kristina Li, Claire Brady, Kenneth Bedi, Yijun Yang, Kaustubh Koya, Emily Megill, Daniel Kanter, Louis Smith, Gregory Bowman, Nathaniel Snyder, Jonathan Edwards, Kenneth Margulies, Zoltan Arany.

Gunsagar Gulati

p53 protein abundance is a therapeutic window across TP53 mutant cancers and is targetable with proximity inducing small molecules

Authors: Ananthan Sadagopan, Nicholas Garaffo, Heng-Jui Chang, Stuart Schreiber, Matthew Meyerson, William Gibson.

Gunsagar Gulati

Source: Gunsagar Gulati/X

Ananthan Sadagopan bioRxiv Caitlyn Bowman cancer Claire Brady Dana-Farber Cancer Institute Deborah Eaton Gunsagar Gulati Heng-Jui Chang Ivan Kuznetsov Jiten Patel Kenneth Bedi Kristina Li Matthew Meyerson Nicholas Forelli Nicholas Garaffo OncoDaily Oncology p53 P53-mutant cancers Ryo Kawakami SGLT2i Stuart Schreiber The Arany lab William Gibson Yijun Yang

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage